Paper40282924
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.
Vruzhaj I and 5 others. Medicina (Kaunas), 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Papers, record 40282924. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40282924
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glypicans | Major topic |
| Pancreatic Neoplasms | Major topic |
| Escherichia coli | Major topic |
| Immunotherapy | Major topic |
| Gastrointestinal Microbiome | Major topic |
| Animals | |
| Mice | |
| Administration, Oral | |
| Humans | |
| Cancer Vaccines | |
| Cell Line, Tumor | |
| Carcinoma, Pancreatic Ductal |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PNRR-M4C2-I1 | The research leading to these results has received funding from the European Un-ion-NextGenerationEU through the Italian Ministry of University and Research under PNRR-M4C2-I1.3 Project PE_00000019 "HEAL ITALIA" to Giuseppe Toffoli (Spoke 6) (CUP J33C2200 | PubMed |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36839825 | Recent Advances in Cancer Immunotherapy Delivery Modalities. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36839825 | PubMed |
| 2 | 25276427 | Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. | Mol Biol Int | 2014 | https://conductscience.org/library/papers/25276427 | PubMed |
| 3 | 34063669 | B Cells and Microbiota in Autoimmunity. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34063669 | PubMed |
| 4 | 14734740 | Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class I-restricted CD8+ T cells following uptake by human APC. | J Immunol | 2004 | https://conductscience.org/library/papers/14734740 | PubMed |
| 5 | 36804602 | Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. | Gastroenterology | 2023 | https://conductscience.org/library/papers/36804602 | PubMed |
| 6 | 15767015 | Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. | J Microbiol Methods | 2005 | https://conductscience.org/library/papers/15767015 | PubMed |
| 7 | 34616044 | Metabolic modulation of tumours with engineered bacteria for immunotherapy. | Nature | 2021 | https://conductscience.org/library/papers/34616044 | PubMed |
| 8 | 34328099 | Emerging roles of miRNAs in the development of pancreatic cancer. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/34328099 | PubMed |
| 9 | 34583978 | Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer. | Mol Cancer Ther | 2021 | https://conductscience.org/library/papers/34583978 | PubMed |
| 10 | 15489184 | Let's go mucosal: communication on slippery ground. | Trends Immunol | 2004 | https://conductscience.org/library/papers/15489184 | PubMed |
| 11 | 28233802 | Targeting neoantigens to augment antitumour immunity. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/28233802 | PubMed |
| 12 | 16581299 | Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. | Mol Ther | 2006 | https://conductscience.org/library/papers/16581299 | PubMed |
| 13 | 15141160 | Potential therapeutic applications of recombinant, invasive E. coli. | Gene Ther | 2004 | https://conductscience.org/library/papers/15141160 | PubMed |
| 14 | 12219778 | Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. | Am J Clin Pathol | 2002 | https://conductscience.org/library/papers/12219778 | PubMed |
| 15 | 37631987 | Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective. | Viruses | 2023 | https://conductscience.org/library/papers/37631987 | PubMed |
| 16 | 18064304 | Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. | J Clin Invest | 2008 | https://conductscience.org/library/papers/18064304 | PubMed |
| 17 | 27640192 | Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. | Appl Microbiol Biotechnol | 2016 | https://conductscience.org/library/papers/27640192 | PubMed |
| 18 | 11471563 | Genetic modification of intestinal lactobacilli and bifidobacteria. | Curr Issues Mol Biol | 2000 | https://conductscience.org/library/papers/11471563 | PubMed |
| 19 | 28440066 | Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. | Cancer Med | 2017 | https://conductscience.org/library/papers/28440066 | PubMed |
| 20 | 28299466 | Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein. | Cancer Immunol Immunother | 2017 | https://conductscience.org/library/papers/28299466 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42346015 | The Gut Microbiome Dependency Continuum in Drug Discovery: A Unified Pharmacology Framework Linking Clinical Drugs, Natural Products, and Engineered Microbial Therapeutics. | BioTech (Basel) | 2026 | https://conductscience.org/library/papers/42346015 | PubMed |
| 41228299 | Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228299 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40282924
GET https://conductscience.org/api/papers/v1/40282924/references?page=2